{"id":4463,"date":"2025-09-09T18:11:34","date_gmt":"2025-09-09T15:11:34","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4463"},"modified":"2025-09-09T18:11:35","modified_gmt":"2025-09-09T15:11:35","slug":"belief-biomed-announced-successful-completion-of-first-dose-of-bbm-d101-gene-therapy","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/de\/belief-biomed-announced-successful-completion-of-first-dose-of-bbm-d101-gene-therapy\/","title":{"rendered":"Belief BioMed gibt erfolgreichen Abschluss der ersten Dosis der Gentherapie BBM-D101 bekannt"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Belief BioMed, ein innovatives Biotechnologieunternehmen, das sich auf die Entwicklung hochmoderner Gentherapien konzentriert, gab heute bekannt, dass die erste Patientendosis im Rahmen der klinischen Zulassungsstudie (CTR20252461) seines unabh\u00e4ngig entwickelten und produzierten Injektionspr\u00e4parats BBM-D101 zur Behandlung der Duchenne-Muskeldystrophie (DMD) in Peking (China) erfolgreich abgeschlossen wurde.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Die BBM-D101-Injektion, eine AAV-basierte Gentherapie, nutzt ein k\u00fcnstlich hergestelltes Kapsid, um Muskelgewebe effizient anzugreifen. Da es in einer niedrigeren Dosis als vergleichbare ausl\u00e4ndische Produkte verabreicht wird, wird ein hohes Sicherheitsniveau erwartet. Die IND f\u00fcr BBM-D101 wurde 2025 sowohl von der chinesischen National Medical Products Administration (NMPA) als auch von der amerikanischen Food and Drug Administration (FDA) genehmigt.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mehr erfahren<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/de\/belief-biomed-bbm-d101-gene-therapy-phase-1-2-clinical-trial-nct07058662\/\" target=\"_blank\" rel=\"noreferrer noopener\">Klinische Phase-1\/2-Studie zur Gentherapie BBM-D101 beginnt<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Belief BioMed, an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that the registration clinical trial (CTR20252461) of its independently developed and produced BBM-D101 injection for Duchenne Muscular Dystrophy (DMD) has successfully completed the first patient dosing in Beijing, China. BBM-D101 injection, an AAV-based gene therapy, utilizes an engineered capsid to efficiently [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4464,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[199,197,123,137,242,61],"class_list":["post-4463","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-bbm-d101","tag-belief-biomed","tag-china","tag-clinical-trial","tag-clinical-trials","tag-gene-therapy"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/4463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/comments?post=4463"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/4463\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media\/4464"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media?parent=4463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/categories?post=4463"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/tags?post=4463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}